A large investigation found that many patients receiving lifesaving cellular therapies experience hidden blood pressure drops. The study reported that more than half of patients develop orthostatic hypotension within the first month after treatment, underscoring a clinically significant safety signal. The finding raises the practical importance of early monitoring for positional blood pressure changes, where symptoms can be overlooked until complications emerge. For clinicians and cell therapy programs, the work supports tighter post-infusion monitoring protocols to reduce preventable morbidity during immune recovery and treatment-related stress.